A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2017
At a glance
- Drugs Gemigliptin/rosuvastatin (Primary) ; Gemigliptin; Rosuvastatin
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 10 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2016.
- 10 May 2016 Status changed from not yet recruiting to recruiting.